Nobilis Therapeuticshttp://www.nobilistx.com
Xenon-based therapeuticsFri, 18 May 2018 08:12:45 +0000en-UShourly1https://wordpress.org/?v=4.9.6Nobilis Therapeutics will participate in BIO International Convention in Boston, MA on June 4-7, 2018http://www.nobilistx.com/2018/05/nobilis-therapeutics-will-participate-in-bio-international-meeting-in-boston-ma-on-june-4-7/
http://www.nobilistx.com/2018/05/nobilis-therapeutics-will-participate-in-bio-international-meeting-in-boston-ma-on-june-4-7/#respondFri, 18 May 2018 08:11:39 +0000http://www.nobilistx.com/?p=448We are happy to announce that Nobilis Therapeutics team will attend BIO International Convention that will take place on June 4-7 in Boston, MA. We look forward to discussing the progress that the company has made in the last several months and welcome invitations to one-on-one meetings through BIO partnering system and at outside venues.

Please contact us if you plan to be at the conference and would like to meet.

Nobilis Team

]]>http://www.nobilistx.com/2018/05/nobilis-therapeutics-will-participate-in-bio-international-meeting-in-boston-ma-on-june-4-7/feed/0Nobilis Therapeutics Receives a Notice of Allowance from USPTO for a Patent Covering Treatments of Rheumatologic Disorders with Noble Gaseshttp://www.nobilistx.com/2018/03/nobilis-therapeutics-receives-a-notice-of-allowance-from-uspto-for-a-patent-covering-treatments-of-rheumatologic-disorders-with-noble-gases/
http://www.nobilistx.com/2018/03/nobilis-therapeutics-receives-a-notice-of-allowance-from-uspto-for-a-patent-covering-treatments-of-rheumatologic-disorders-with-noble-gases/#respondWed, 14 Mar 2018 07:01:22 +0000http://www.nobilistx.com/?p=443PORTLAND, Ore., March 14, 2017 — Nobilis Therapeutics announced today that the patent that the company filed in June of 2017 has received a notice of allowance. The patent is titled “TREATMENT OF RHEUMATOID ARTHRITIS USING NOBLE GAS MIXTURES” and covers a wide range of noble gas uses in the treatment of rheumatologic diseases.

“This is a major accomplishment for us,” said Dr. Vlad Bogin, company’s CEO. “This patent is based on extensive proprietary data that we were able to collect and analyze through our collaboration with talented researchers from the former Soviet Union who have been experimenting with the use of subanesthetic doses of noble gases to treat a variety of clinical conditions. The source data that we have access to are rather incredible and have allowed us to truly dominate the intellectual property domain in our field of interest.”

“I am very excited to see how my research of medical applications of noble gases is being steadily advanced towards clinical practice. It is simply astounding that an inert gas can possess anti-inflammatory properties and shows reproducible reduction in the levels of several cytokines not only in the central nervous system but also systemically.” said Dr. Alexander Dobrovolsky, MD, PhD, company’s core expert.

About Nobilis Therapeutics, Inc.

Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have an exceptional safety profile proven by decades of clinical use. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in the treatment of over 2000 patients for conditions ranging from panic attacks to substance abuse.

Contact Information:

Vlad Bogin, MD, FACP

3042 NW Monte Vista Terrace

Portland, OR 97210

Tel: (971) 229-1679

Email: vbogin@nobilistx.com

Website: http://www.nobilistx.com

Twitter: @nobilistx

]]>http://www.nobilistx.com/2018/03/nobilis-therapeutics-receives-a-notice-of-allowance-from-uspto-for-a-patent-covering-treatments-of-rheumatologic-disorders-with-noble-gases/feed/0Nobilis Therapeutics issues a press release after a productive meeting with the House of Representatives Committee on Veterans’ Affairs.http://www.nobilistx.com/2018/02/nobilis-therapeutics-issues-a-press-release-after-a-productive-meeting-with-the-house-of-representatives-committee-on-veterans-affairs/
http://www.nobilistx.com/2018/02/nobilis-therapeutics-issues-a-press-release-after-a-productive-meeting-with-the-house-of-representatives-committee-on-veterans-affairs/#respondFri, 23 Feb 2018 22:50:46 +0000http://www.nobilistx.com/?p=440

Nobilis Therapeutics Presents Its PTSD Clinical Development Program To The US Congress

As PTSD treatment remains a critical unmet need there is heightened public and private interest in identifying new and safe treatments for this devastating disease. This sentiment has been clearly verbalized during the meeting in Washington.

“We appreciate the opportunity to present our approach to PTSD treatment to the House of Representatives Committee on Veteran’s Affairs and look forward to the launch of Phase IIb/III trial with the support and encouragement from the US Congress and relevant government stakeholders within Veteran’s Administration and the DoD,” said Dr. Bogin, Nobilis Therapeutics’ CEO.

Nobilis Therapeutics recently held a pre-IND meeting with the FDA and received a very positive feedback on the proposal to run a late stage clinical trial with its Xenon-based therapeutic candidate. The company plans to submit an IND in the coming weeks.

“This was an incredible opportunity to interface with VA representatives and make them aware of our cutting-edge preclinical work to understand the neurobiology underlying maladaptive emotional memories, and test innovative treatments that can be rapidly translated to humans with PTSD. Given the paucity of effective pharmacotherapies for treating PTSD, I believe that advancing collaborations between government, industry and academia will foster the much-needed breakthroughs in the treatment of this debilitating disorder,” said Dr. Edward Meloni, Assistant Professor of Psychiatry at Harvard-affiliated McLean Hospital.

The company is very encouraged by a recent position statement from the PTSD psychopharmacology working group that identified NMDA receptor blockade as the most promising target in the treatment of PTSD. Given that Xenon is an NMDA receptor antagonist with an exceptional safety profile and strong preclinical and clinical signals of efficacy, if it shows positive results in the upcoming clinical trial, it could become a game changer not only in the treatment of PTSD but in many other psychiatric indications.

About the company

Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using portable device administration of inert gases that have an exceptional safety profile proven by decades of clinical use. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in the treatment of over 500 patients for conditions ranging from panic attacks to substance abuse.

Vlad Bogin, MD, FACP

3042NW Monte Vista Terrace

Portland, OR 97210

Tel: (971) 229-1679

Email: vlad.bogin@nobilistx.com

Website: http://www.nobilistx.com

Twitter: @nobilistx

]]>http://www.nobilistx.com/2018/02/nobilis-therapeutics-issues-a-press-release-after-a-productive-meeting-with-the-house-of-representatives-committee-on-veterans-affairs/feed/0On February 21st Nobilis Therapeutics will present its PTSD clinical program to the US Congresshttp://www.nobilistx.com/2018/02/on-february-21st-nobilis-therapeutics-will-present-its-ptsd-clinical-program-to-the-us-congress/
http://www.nobilistx.com/2018/02/on-february-21st-nobilis-therapeutics-will-present-its-ptsd-clinical-program-to-the-us-congress/#respondSun, 18 Feb 2018 15:25:53 +0000http://www.nobilistx.com/?p=437Drs. Meloni and Bogin were invited to discuss Nobilis Therapeutics’ PTSD clinical development program in front of the US Congress. As treatment for PTSD remains a tremendous unmet need, there is a significant interest on the part of the Congress, VA, DoD and other agencies to make sure that the best drug candidates have every chance to make it through clinical testing.
After a very positive pre-IND meeting the Company is getting ready to file an IND for its phase IIb-III clinical trial where its leading drug-device combination, NBTX-001 will be tested against placebo. Given very strong preclinical data and encouraging results of its ex-US Panic Disorder study the Company is very optimistic about this upcoming trial.
Please stay tuned for more exciting news from Nobilis Therapeutics!
]]>http://www.nobilistx.com/2018/02/on-february-21st-nobilis-therapeutics-will-present-its-ptsd-clinical-program-to-the-us-congress/feed/0Nobilis Therapeutics will present its clinical study of the use of NBTX-001 in patients with Panic Disorder at the ADAA annual meetinghttp://www.nobilistx.com/2018/01/nobilis-therapeutics-will-present-its-clinical-study-of-the-use-of-nbtx-001-in-patients-with-panic-disorder-at-the-adaa-annual-meeting/
http://www.nobilistx.com/2018/01/nobilis-therapeutics-will-present-its-clinical-study-of-the-use-of-nbtx-001-in-patients-with-panic-disorder-at-the-adaa-annual-meeting/#respondThu, 01 Feb 2018 00:07:51 +0000http://www.nobilistx.com/?p=426In early April Nobilis Therapeutics will present the results of its clinical trial of NBTX-001 in patients with Panic Disorder at the annual conference of Anxiety and Depression Association of America (ADAA). This is the first documented study of xenon-based therapeutic in patients with psychiatric disorder. The study was publishedin the Journal of Translational Medicine in June of 2017.
]]>http://www.nobilistx.com/2018/01/nobilis-therapeutics-will-present-its-clinical-study-of-the-use-of-nbtx-001-in-patients-with-panic-disorder-at-the-adaa-annual-meeting/feed/0Nobilis Therapeutics to attend J.P.Morgan’s 36th Annual Healthcare Conferencehttp://www.nobilistx.com/2017/12/408/
http://www.nobilistx.com/2017/12/408/#respondWed, 20 Dec 2017 08:35:32 +0000http://www.nobilistx.com/?p=408Nobilis Therapeutics leadership will be attending J.P.Morgan’s 36th Annual Healthcare Conference that will take place in San Francisco on January 8-11. If you are interested in setting up a f2f meeting with our team, please send us an email.
]]>http://www.nobilistx.com/2017/12/408/feed/0Yulii Bogatyrenko, a seasoned pharmaceutical executive, joins Nobilis Therapeutics as its Chief Operating Officerhttp://www.nobilistx.com/2017/10/yulii-bogatyrenko-a-seasoned-pharmaceutical-executive-joins-nobilis-therapeuticsas-as-its-chief-operating-officer/
http://www.nobilistx.com/2017/10/yulii-bogatyrenko-a-seasoned-pharmaceutical-executive-joins-nobilis-therapeuticsas-as-its-chief-operating-officer/#respondFri, 27 Oct 2017 01:04:42 +0000http://www.nobilistx.com/?p=359Mr. Bogatyrenko is a proven pharmaceutical executive, having served in multiple operational and consulting roles in the life sciences industry. Most recently he was a SVP, Business Development at Paratek Pharmaceuticals in Boston where he developed global and regional partnerships for its anti-infective products and led its U.S. alliance with Allergan. He is a Venture Partner at ATEM Capital in New York, where he developed commercial strategies for clients across a variety of therapeutic areas. Prior to ATEM, he held the position of Vice President and General Manager at Teva Specialty Pharmaceuticals. In this role, he directed biopharma and over-the-counter (OTC) women’s health business across emerging markets, and was responsible for business development of Teva’s women’s health portfolio, including biologics, small molecules, and OTC products. Yulii holds an MBA in Finance from L. Stern School of Business, NYU.
]]>http://www.nobilistx.com/2017/10/yulii-bogatyrenko-a-seasoned-pharmaceutical-executive-joins-nobilis-therapeuticsas-as-its-chief-operating-officer/feed/0PTSD Psychopharmacology Working Group calls attention to the crisis in PTSD pharmacotherapy and identifies NMDA receptor antagonism as the most promising target for future treatments.http://www.nobilistx.com/2017/10/ptsd-psychopharmacology-working-groupcalls-attention-to-the-crisis-in-ptsd-pharmacotherapy-and-identifies-nmda-receptor-antagonism-as-the-most-promising-target-for-future-treatments/
http://www.nobilistx.com/2017/10/ptsd-psychopharmacology-working-groupcalls-attention-to-the-crisis-in-ptsd-pharmacotherapy-and-identifies-nmda-receptor-antagonism-as-the-most-promising-target-for-future-treatments/#respondThu, 05 Oct 2017 17:45:55 +0000http://www.nobilistx.com/?p=432A consensusstatement of the PTSD Psychopharmacology Working Group has clearly identified treatment of PTSD, a disease without any effective pharmacotherapy, as a severe unmet medical need. The group has analyzed scientific data on potential efficacy of a multitude of receptor targets and identified NMDA receptor antagonism as the most promising approach to future treatments.
]]>http://www.nobilistx.com/2017/10/ptsd-psychopharmacology-working-groupcalls-attention-to-the-crisis-in-ptsd-pharmacotherapy-and-identifies-nmda-receptor-antagonism-as-the-most-promising-target-for-future-treatments/feed/0Nobilis Therapeutics’ NBTX-001 shows promise in treatment of patients with Panic Disorder. Study results published in Journal of Translational Medicine.http://www.nobilistx.com/2017/06/nobilis-therapeutics-nbtx-001-shows-promise-in-treatment-of-patients-with-panic-disorder-study-results-published-in-journal-of-translational-medicine/
http://www.nobilistx.com/2017/06/nobilis-therapeutics-nbtx-001-shows-promise-in-treatment-of-patients-with-panic-disorder-study-results-published-in-journal-of-translational-medicine/#respondThu, 15 Jun 2017 02:00:34 +0000http://www.nobilistx.com/?p=345Nobilis Therapeutics published the results of its pioneering clinical trial on 81 patients with Panic Disorder in the Journal of Translational Medicine. Patients were treated with NBTX-001 with remarkable results. This study validates the company’s methodology and paves the way to the upcoming studies in PTSD and Alzheimer’s Dementia. Please click here to read the original article and here to read the press release.
]]>http://www.nobilistx.com/2017/06/nobilis-therapeutics-nbtx-001-shows-promise-in-treatment-of-patients-with-panic-disorder-study-results-published-in-journal-of-translational-medicine/feed/0Nobilis Therapeutics receives a notice of allowance for a patent covering treatment of psychiatric disorders with noble gaseshttp://www.nobilistx.com/2017/06/nobilis-therapeutics-receives-a-notice-of-allowance-for-a-patent-covering-treatment-of-psychiatric-disorders-with-noble-gases/
http://www.nobilistx.com/2017/06/nobilis-therapeutics-receives-a-notice-of-allowance-for-a-patent-covering-treatment-of-psychiatric-disorders-with-noble-gases/#respondTue, 13 Jun 2017 08:37:02 +0000http://www.nobilistx.com/?p=341Nobilis Therapeutics has received a notice of allowance for its most important patent. The patent covers the uses of noble gas-based therapies in a variety of psychiatric illnesses. Please read our press release here.
]]>http://www.nobilistx.com/2017/06/nobilis-therapeutics-receives-a-notice-of-allowance-for-a-patent-covering-treatment-of-psychiatric-disorders-with-noble-gases/feed/0